Allergan

Allergan's global headquarters are located in Dublin, Ireland. The company also maintains a significant presence in the United States, with administrative and operational headquarters located in various locations across the country, including Irvine, California and Madison, New Jersey.{{cite web | url=https://dkdermal.com/blog/botulinum/history-of-actavis/ | title=History of Allergan | date=March 2023 }}

Allergan plc was created from the 2015 merger and Irish corporate tax inversion of two companies, Irish-based Actavis plc and U.S.-based Allergan, Inc.{{Cite web|url=https://www.businessinsider.com/allergan-history-since-1948-founding-2015-11|title=How Allergan went from a tiny Los Angeles eye care company to the biggest takeover target of 2015|last=Ramsey|first=Lydia|website=Business Insider|access-date=2020-04-07}}

File:Allergan headquarters.jpg]]

In 1948, pharmacist Gavin S. Herbert founded Allergan Pharmaceuticals, Inc. In 1970, Allergan, Inc. became a public company via an initial public offering. In 1977, Allergan announced plans to build a factory in Westport, Ireland.{{Cite journal|date=2020-01-28|title=Allergan opens new €160m biologics plant in Westport|url=https://www.rte.ie/news/business/2020/0128/1111363-allergan-mayo-expansion/|journal=RTÉ.ie|language=en}}

In 1980, it was acquired by SmithKline Corporation for $259 million{{Cite book|url=https://books.google.com/books?id=ODLnFzyuy0QC&q=Allergan+was+acquired+by+SmithKline+Corporation+1980|title=Federal Trade Commission Decisions|date=July 1980|publisher=U.S. Government Printing Office|language=en}} and was later spun-off by SmithKline Beecham in 1989.{{cite news | url=https://www.latimes.com/archives/la-xpm-1989-07-27-fi-352-story.html | title=Shareholders OK SmithKline Deal Spinning Off Beckman, Allergan | last=Berkman | first=Leslie | work=Los Angeles Times | date=July 27, 1989}} In 1989, Allergan opened a manufacturing plant in Waco, Texas, to manufacture eye care products.{{Cite web|url=https://www.wacotrib.com/business/allergan-with-waco-plant-could-be-sold-in-63-billion-deal/article_0a8f9024-dd1b-5b4e-8e06-9c74df0c83ad.html|title=Allergan, with Waco plant, could be sold in $63 billion deal|last=Copeland|first=Mike|website=WacoTrib.com|language=en|access-date=2020-04-07}}

In 1991, Allergan acquired the company Oculinum which manufactured products for eye muscle disorders.{{Cite magazine|url=https://www.newyorker.com/business/currency/actavis-allergan-botox-sale|title=Billions and Billions for Botox|last=Vara|first=Vauhini|magazine=The New Yorker|date=18 November 2014|language=en|access-date=2020-04-07}}{{Cite news|agency=Associated Press|url=https://www.nytimes.com/1990/01/09/science/eye-drug-approved-by-fda.html|title=Eye Drug Approved By F.D.A.|date=1990-01-09|work=The New York Times|access-date=2020-04-07|language=en-US|issn=0362-4331}} Following the acquisition, the product was renamed Botox.{{Cite web|url=https://www.healio.com/ophthalmology/neurosciences/news/print/ocular-surgery-news/%7Be495ae1c-de2c-42de-97dd-a95b0f0977cf%7D/taking-a-chance-on-botox-paid-off-for-allergan|title=Taking a chance on Botox paid off for Allergan|date=31 May 2018|website=www.healio.com|language=en|access-date=2020-04-07|last=Steinert|first=April}} In 1996, Allergan received FDA approval for Alphagan ophthalmic solution for open-angle glaucoma and ocular hypertension.{{Cite web|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020613s031lbl.pdf|archive-url=https://web.archive.org/web/20170216212711/http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020613s031lbl.pdf|url-status=dead|archive-date=February 16, 2017|title=ALPHAGAN (brimonidine tartrate ophthalmic solution)|date=2016|website=fda.gov}} In 1998, Allergan established The Allergan Foundation, a private US-based charitable foundation.{{Cite web|url=https://www.bizjournals.com/cincinnati/news/2019/04/15/allergen-discloses-economic-impact-of-cincinnati.html|title=Allergan discloses economic impact of Cincinnati plant|website=www.bizjournals.com|access-date=2020-04-07}}

In 2005, Allergan acquired Inamed which had a licensing agreement with Corneal Group Laboratoires for Juvederm products.{{Cite web|url=https://www.latimes.com/archives/la-xpm-2005-dec-16-fi-calbriefs16.4-story.html|title=Inamed Says Board Approves Allergan Offer|date=2005-12-16|website=Los Angeles Times|language=en-US|access-date=2020-04-07}}{{Cite web|url=https://www.healio.com/ophthalmology/ophthalmic-business/news/online/%7Be58fefeb-b8d1-442b-a0b9-5d96e02df58c%7D/allergan-reports-158-increase-in-2006-eye-care-pharmaceutical-sales|title=Allergan reports 15.8% increase in 2006 eye care pharmaceutical sales|date=February 2, 2007|website=www.healio.com|language=en|access-date=2020-04-07}}{{Cite web|url=https://www.sec.gov/Archives/edgar/data/850693/000095013707003060/a27376e10vk.htm|title=e10vk - Allergan, Inc.|website=www.sec.gov|access-date=2020-04-07}} In 2006, Allergan gained rights to Juvederm products.{{Cite web|url=https://www.thepharmaletter.com/article/allergan-buys-groupe-corneal-for-217m|title=Allergan buys Groupe Corneal for $217M - Pharmaceutical industry news|website=www.thepharmaletter.com|access-date=2020-04-07}}{{Cite news|url=https://www.reuters.com/article/allergan-fda-dermalfiller-idUSL3N0DH34U20130430|title=FDA staff says Allergan's new dermal filler effective|date=2013-04-30|work=Reuters|access-date=2020-04-07|language=en}}

In the spring of 1983, colleagues Allen Chao and David Hsia formed Watson Pharmaceuticals, a drug development in Libertyville, Illinois.{{Cite web|url=https://www.purdue.edu/newsroom/releases/2016/Q4/pharmaceutical-leader-and-purdue-alumnus-brings-expertise-to-purdue-based-contract-drug-manufacturing-organization.html|title=Pharmaceutical leader and Purdue alumnus brings expertise to Purdue-based contract drug manufacturing organization|agency=Purdue News Service|website=www.purdue.edu|language=en|access-date=2020-04-07}} In late fall of 1983, the company moved to Corona, California, and began to develop and manufacture generic pharmaceuticals.{{Cite web|url=https://www.latimes.com/archives/la-xpm-1996-06-12-fi-14183-story.html|title=Prescription for Success : Drug Maker Watson Thrives in Crowded Generic Market|date=1996-06-12|website=Los Angeles Times|language=en-US|access-date=2020-04-07}} In February 1993, the company became a public company via an initial public offering.

In 2011, the company moved its corporate headquarters from Corona, California, to Parsippany-Troy Hills, New Jersey.{{cite news|last=Todd|first=Susan|url=http://www.nj.com/business/index.ssf/2012/01/generic_drug_maker_watson_open.html|title=Generic drug maker Watson opening research operations in North Brunswick|date=January 30, 2012|work=NJ.com}}{{Cite web|url=https://www.pe.com/2014/01/02/industry-corona-pharmaceuticals-plant-to-focus-on-contraceptives-now/|title=INDUSTRY: Corona pharmaceuticals plant to focus on contraceptives now|date=2014-01-02|website=Press Enterprise|language=en-US|access-date=2020-04-07}} On October 31, 2012, Watson acquired Actavis for {{Euro|4.25 billion|link=yes}} and took the Actavis name.{{Cite news|url=https://www.reuters.com/article/uk-watson-actavis-idUKBRE83O1B820120426|title=Watson to buy Actavis for at least 4.25 billion euros|date=2012-04-26|work=Reuters|access-date=2020-04-07|language=en}} In 2013, Actavis acquired Irish-registered Warner Chilcott for $5 billion and used the transaction to execute a corporate tax inversion to Ireland.{{cite news|url=https://www.ft.com/content/4d5df734-c147-11e2-9767-00144feab7de|title=Actavis to acquire Warner Chilcott in $5bn pharmaceutical deal|date=20 May 2013|newspaper=Financial Times|quote=Actavis sought to fend off takeover threats by purchasing Dublin-based rival Warner Chilcott in a $5bn deal designed to turn it into the world's third-largest generic drug company by sales. The agreed all-stock deal, worth $8.5bn including net debt, follows recent efforts by competitors including Valeant and Mylan to acquire Actavis. Analysts said the move could spark alternative bids for Actavis or Warner Chilcott at a time of rapid consolidation in the sector. [..] The transaction will also exploit tax savings through the creation of a new Irish holding company, cutting Actavis' estimated 28 percent tax rate this year to 17 per cent and helping create annual synergies that the company said would exceed $400m.}}{{Cite news|last=Mattioli|first=Dana|url=https://www.wsj.com/articles/potential-actavis-allergan-deal-paves-way-for-tax-savings-1416183632|title=Actavis-Allergan Deal Paves Way for Tax Savings|date=2014-11-17|work=Wall Street Journal|access-date=2020-04-07|language=en-US|issn=0099-9660}} In 2014, Actavis acquired Forest Laboratories for $25 billion.{{Cite news|last=Cimilluca|first=Dana Mattioli, Jonathan D. Rockoff and Dana|url=https://www.wsj.com/articles/actavis-to-buy-forest-labs-for-25-billion-1392725732|title=Actavis Agrees to Buy Forest Labs for $25 Billion|date=2014-02-18|work=Wall Street Journal|access-date=2020-04-07|language=en-US|issn=0099-9660}}

{{See also|Corporation tax in the Republic of Ireland#Corporate tax inversions}}

File:Allergan Headquarters in Ireland (Clonsaugh Park, Coolock, Dublin).jpg

In 2015, Irish-based Actavis plc acquired U.S.-based Allergan, Inc., for $70 billion, and in effect redomiciled Allergan to Ireland in a corporate tax inversion.{{Cite web|url=https://www.thestreet.com/politics/as-treasury-moves-to-bring-back-inversions-here-are-seven-of-the-biggest-recent-deals-html|title=As Treasury Moves to Bring Back Inversions, Here are 7 of the Biggest Recent Deals|last=Stewart|first=Emily|website=TheStreet|language=en-us|access-date=2020-04-07}} Actavis CEO Brent Saunders became the CEO of the combined company.{{Cite web|url=https://www.businessinsider.com/history-of-botox-maker-allergan-2018-6|title=Allergan started out as a tiny but beloved Southern California eye care firm before expanding to a $130 billion company. Here's how the Botox-maker fell out grace with investors and then became a takeover target.|last=Ramsey|first=Lydia|website=Business Insider|access-date=2020-04-07}} In June 2015, the company took the Allergan name.{{Cite web|url=https://www.biospace.com/article/actavis-officially-changes-name-to-allergan-/|title=Actavis Officially Changes Name to Allergan|website=BioSpace|language=en-US|access-date=2020-04-07}}

As of 2020, the company operated four facilities in Ireland.{{Cite web|url=https://www.independent.ie/business/irish/allergan-launches-145m-botox-site-as-merger-nears-38905999.html|title=Allergan launches €145m Botox site as merger nears|website=independent|language=en|access-date=2020-04-07}}

On July 7, 2015, the company acquired the rights to the late stage CGRP migraine portfolio of Merck & Co, as well as two experimental drugs for an upfront payment of $250 million.{{cite news | last=Dulaney | first=Chelsey | title=Allergan Buys Rights to Merck's Migraine Drugs | url=https://www.wsj.com/articles/allergan-buys-rights-to-mercks-migraine-drugs-1436268370 | work=The Wall Street Journal | date=July 7, 2015 |url-access=subscription }} Later that summer, the company acquired Oculeve for $125 million{{Cite web|url=https://www.medicaldevice-network.com/news/newsallergan-medical-device-firm-oculeve-4644342/|title=Allergan buys medical device firm Oculeve for $125m|date=2015-08-10|website=Verdict Medical Devices|language=en-GB|access-date=2020-04-08}} and Naurex for an upfront payment of $560 million.{{Cite news|last=Stahl|first=George|url=https://www.wsj.com/articles/allergan-to-acquire-naurex-for-560-million-cash-1437918753|title=Allergan to Acquire Naurex for $560 Million Cash|date=2015-07-26|work=Wall Street Journal|access-date=2020-04-08|language=en-US|issn=0099-9660}} In October 2015, the company acquired AqueSys, developer of ocular implants for an initial payment of $300 million,{{Cite web|url=https://www.healio.com/ophthalmology/ophthalmic-business/news/online/%7B0e1aa516-a3e9-43cb-ac4c-06018cdee89c%7D/allergan-to-acquire-aquesys|title=Allergan to acquire AqueSys|date=September 4, 2015|website=www.healio.com|language=en|access-date=2020-04-08}} along with Kythera Biopharmaceuticals, a company focused on the medical aesthetics market, for $2.1 billion.{{Cite news|last=Bray|first=Chad|url=https://www.nytimes.com/2015/06/18/business/dealbook/allergan-to-buy-kythera-biopharmaceuticals-for-2-1-billion.html|title=Allergan to Buy Kythera Biopharmaceuticals for $2.1 Billion|date=2015-06-17|work=The New York Times|access-date=2020-04-08|language=en-US|issn=0362-4331}}{{Cite web|url=https://www.sec.gov/Archives/edgar/data/1620602/000119312515335373/d95661d8k.htm|title=Form 8-K - Warner Chilcott Limited|date=October 2015|website=www.sec.gov|access-date=2020-04-08}}

In late 2015, the company announced the acquisition of Northwood Medical Innovation, the developer of earFold.{{Cite web|url=https://www.healio.com/aesthetics/business-of-aesthetics/news/online/%7Be010b424-93d5-429a-919f-b24b948ef4f6%7D/allergan-agrees-to-acquire-earfold-device-for-correcting-prominent-ears|title=Allergan agrees to acquire earFold device for correcting prominent ears|date=November 5, 2015|website=www.healio.com|language=en|access-date=2020-04-08}} On November 25, 2015, the company announced it would partner with Rugen Therapeutic to develop new therapies for autism spectrum disorder and obsessive compulsive disorder.{{Cite web|url=https://www.thepharmaletter.com/article/allergan-and-rugen-therapeutics-team-up-on-autism-and-ocd-research|title=Allergan and Rugen Therapeutics team up on autism and OCD research|website=www.thepharmaletter.com|access-date=2020-04-08}}

On November 23, 2015, Allergan and Pfizer announced their intention to merge in a $160 billion transaction.{{cite news | url=https://www.bbc.co.uk/news/business-34900344 | title=Pfizer seals $160bn Allergan deal to create drugs giant | work=BBC News | date=November 23, 2015}} On April 5, 2016, after the Obama administration announced its plan to ban tax inversions, Pfizer terminated the acquisition and paid Allergan a $150 million breakup fee.{{cite news | last=Rockoff | first=Jonathan | title=Pfizer Walks Away From Allergan Deal | url=https://www.wsj.com/articles/pfizer-walks-away-from-allergan-deal-1459939739 | work=The Wall Street Journal | date=April 6, 2016 |url-access=subscription }}{{Cite news|last=Hoffman|first=Richard Rubin and Liz|url=https://www.wsj.com/articles/u-s-treasury-unveils-new-steps-to-limit-tax-inversions-1459803636|title=New Rules on Tax Inversions Threaten Pfizer-Allergan Deal|date=2016-04-05|work=Wall Street Journal|access-date=2020-04-08|language=en-US|issn=0099-9660}}

In April 2016, the company announced it would partner with Heptares Therapeutics to develop a subtype-selective muscarinic agonists for Alzheimer's disease{{Cite web|url=https://www.fiercebiotech.com/partnering/solo-again-allergan-strikes-a-3-3b-deal-on-heptares-alzheimer-s-portfolio|title=Solo again, Allergan strikes a $3.3B deal on Heptares' Alzheimer's portfolio|website=FierceBiotech|language=en|access-date=2020-04-08}}{{Cite web|url=https://www.sec.gov/Archives/edgar/data/1578845/000156459016027705/agn-10q_20160930.htm|title=Form 10-Q - ALLERGAN PLC|date=September 30, 2016}} and announced the acquisition of Topokine Therapeutics, gaining the phase IIb/III compound XAF5 - a treatment for dermatochalasis.{{Cite web|url=https://www.biospace.com/article/allergan-makes-another-deal-bags-boston-s-topokine-for-85-million-/|title=Allergan Makes Another Deal, Bags Boston's Topokine for $85 Million+|website=BioSpace|language=en-US|access-date=2020-04-08}}

In August 2016, Allergan plc sold its generic drugs business to Teva Pharmaceutical Industries in a $40.5 billion deal{{Cite web|url=https://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1066.htm|title=EX-10.66 - SETTLEMENT AGREEMENT AND MUTUAL RELEASES|website=www.sec.gov|access-date=2020-04-08}}{{Cite web|url=https://www.bizjournals.com/philadelphia/morning_roundup/2016/08/teva-buying-anda-for-500-million-actavis.html|title=Teva completes $40.5B Actavis deal, enters into $500M for generics distributor|website=www.bizjournals.com|access-date=2020-04-08}} and announced the acquisition of ForSight VISION5 for more than $95 million.{{Cite web|url=https://www.thestreet.com/markets/mergers-and-acquisitions/allergan-scoops-up-yet-another-biotech-company-13870974|title=Allergan scoops up yet another biotech company|last=McElhaney|first=Alicia|website=TheStreet|language=en-us|access-date=2020-04-08}}

In September 2016, CEO Saunders announced what he called a social contract to limit prices on the company's medications.{{Cite web|url=https://www.lifescienceleader.com/doc/behind-the-scenes-of-allergan-s-social-contract-0001|title=Behind The Scenes Of Allergan's Social Contract|website=www.lifescienceleader.com|access-date=2020-04-08}}{{Cite web|url=https://fortune.com/2016/09/06/allergan-drug-price-hike-promise-saunders/|title=Allergan CEO Saunders Promises Responsible Drug Prices in 'Contract'|website=Fortune|language=en|access-date=2020-04-08}} That same month, the company acquired RetroSense Therapeutics for more than $60 million,{{Cite web|url=https://www.healio.com/ophthalmology/ophthalmic-business/news/online/%7Bf11781cf-2782-4097-b3ff-b03fe7da8ec3%7D/allergan-acquires-retrosense-therapeutics|title=Allergan acquires RetroSense Therapeutics|date=September 7, 2016|website=www.healio.com|language=en|access-date=2020-04-08}} announced the acquisition of Tobira Therapeutics for approximately $1.7 billion{{cite news | title=Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal | url=https://www.wsj.com/articles/allergan-agrees-to-buy-tobira-therapeutics-in-1-7-billion-deal-1474376639 | first=Tess | last=Stynes | work=The Wall Street Journal | date=September 20, 2016 |url-access=subscription }} and, a day later, the acquisition of Akarna Therapeutics for $50 million.{{cite news | title=Allergan to Acquire U.K.'s Akarna Therapeutics | url=https://www.wsj.com/articles/allergan-to-acquire-u-k-s-akarna-therapeutics-1474456238 | first=Tess | last=Stynes | work=The Wall Street Journal | date=September 21, 2016 |url-access=subscription }}

In October 2016, the company sold Anda, its generic drug distribution business, to Teva for $500 million{{Cite web|url=https://www.sec.gov/Archives/edgar/data/1578845/000156459019003111/agn-10k_20181231.htm|title=FORM 10-K-ALLERGAN PLC - WARNER CHILCOTT LIMITED|date=December 2018}}{{Cite news|url=https://www.reuters.com/article/us-allergan-m-a-teva-pharm-ind-idUSKCN10E1NE|title=Allergan to sell Anda drug distribution business to Teva|date=2016-08-03|work=Reuters|access-date=2020-04-08|language=en}} and acquired Vitae Pharmaceuticals, focused on dermatology treatments, for $639 million.{{Cite news|last=Hufford|first=Austen|url=https://www.wsj.com/articles/allergan-to-buy-vitae-pharmaceuticals-for-639-million-1473857881|title=Allergan to Buy Vitae Pharmaceuticals for $639 Million|date=2016-09-14|work=Wall Street Journal|access-date=2020-04-08|language=en-US|issn=0099-9660}}{{Cite web|url=https://practicaldermatology.com/news/allergan-completes-vitae-tender-offer|title=Allergan Completes Vitae Tender Offer|website=Practical Dermatology|language=en|access-date=2020-04-08}} That same month, the company announced it would acquire Motus Therapeutics, a developer of treatments for gastrointestinal disorders, for $200 million.{{Cite web|url=https://www.bizjournals.com/boston/news/2016/10/27/allergan-to-acquire-boston-drug-company-for-200m.html|title=Allergan to acquire Boston drug company for $200M|website=www.bizjournals.com|access-date=2020-04-08}} On November 22, 2016, the company acquired Chase Pharmaceuticals for $125 million.{{Cite web|url=https://www.businessinsider.com/r-brief-allergan-completes-acquisition-of-chase-pharmaceuticals-2016-11|title=BRIEF-Allergan completes acquisition of Chase Pharmaceuticals|website=Business Insider|access-date=2020-04-08}}{{Cite web|url=https://realmoney.thestreet.com/articles/11/25/2016/allergan-could-pay-1-billion-chase-pharma|title=Allergan could pay $1 billion for chase pharma|date=2016-11-25|website=RealMoney|language=en|access-date=2020-04-08}}

In 2017, the company acquired LifeCell, a specialist in regenerative medicine, for $2.9 billion and Zeltique Aesthetics, maker of CoolSculpting, for $2.4 billion.{{Cite news|url=https://www.reuters.com/article/us-zeltiq-m-a-allergan-idUSKBN15S1G1|title=Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion|date=2017-02-13|work=Reuters|access-date=2020-04-08|language=en}}{{Cite web|url=https://www.spglobal.com/marketintelligence/en/news-insights/trending/x-7xp_tmgbvnydmvhxyjra2|title=Allergan completes $2.9B LifeCell acquisition|website=www.spglobal.com|language=en-us|access-date=2020-04-08}}{{Cite web|url=https://fortune.com/2017/02/13/allergan-zeltiq-acquisition/|title=Allergan Will Buy Zeltiq for $2.48 Billion|website=Fortune|language=en|access-date=2020-04-08}}{{Cite web|url=https://www.businessinsider.com/r-brief-allergan-completes-zeltiq-acquisition-2017-4|title=BRIEF-Allergan completes Zeltiq acquisition|website=Business Insider|access-date=2020-04-08}} On June 7, the company announced the acquisition of Keller Medical, a company that manufactures devices for use during breast augmentation surgery.{{Cite web|url=https://www.foxbusiness.com/markets/allergan-to-buy-medical-device-company-and-breast-surgery-funnel-maker-keller-medical-inc|title=Allergan To Buy Medical Device Company And Breast Surgery Funnel-maker Keller Medical Inc.|date=2017-06-07|website=Fox Business - MarketWatch Pulse|language=en-US|access-date=2020-04-08}} On December 12, the company announced the acquisition of Repros Therapeutics, a developer of drugs for reproductive system diseases.{{Cite web|url=https://www.biospace.com/article/unique-allergan-swoops-in-and-bags-troubled-repros-therapeutics/|title=Allergan Swoops in and Bags Troubled Repros Therapeutics|website=BioSpace|language=en-US|access-date=2020-04-08}}

In September 2018, Allergan acquired the aesthetic company, Bonti, for $195 million.{{cite web|url=https://www.biospace.com/article/am6a-botox-maker-allergan-buys-aesthetic-company-bonti-for-195-million-up-front/|title=Botox Maker Allergan Buys Aesthetic Company Bonti for $195 Million Up Front|website=BioSpace}}{{cite web|url=https://www.biospace.com/article/allergan-to-acquire-bonti-adding-new-neurotoxin-programs-to-medical-aesthetics-pipeline/|title=Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline|website=BioSpace}}

In March 2019, the company acquired Envy Medical, Inc.{{cite web|url=https://www.biospace.com/article/allergan-acquires-envy-medical-inc-adding-skin-resurfacing-dermalinfusion-system-to-best-in-class-medical-aesthetics-portfolio/|title=Allergan Acquires Envy Medical, Inc., Adding Skin Resurfacing Dermalinfusion System to Best-in-Class Medical Aesthetics Portfolio|website=BioSpace}} As of 2019, Allergan's Botox product had annual sales of nearly $4 billion.{{Cite web|url=https://www.fiercepharma.com/manufacturing/allergan-unveils-new-botox-plant-63b-abbvie-merger-edges-to-completion|title=Allergan unveils new Botox plant ahead of $63B AbbVie merger|website=FiercePharma|language=en|access-date=2020-04-08}}

In 2018, along with several other drug manufacturers and distributors, the company was sued by several municipalities and states in the U.S. due to the manufacture of opioids, which have been abused in what has been referred to as the opioid epidemic.{{cite news|last=Stempel|first=Jonathan|url=https://www.reuters.com/article/us-usa-opioids-litigation-newyorkcity/new-york-city-sues-drug-companies-over-opioid-epidemic-idUSKBN1FC2GK|title=New York City sues drug companies over opioid epidemic|date=January 23, 2018|work=Reuters}}{{Cite news|last1=Gurman|first1=Sadie|url=https://www.dddmag.com/news/2018/03/doj-support-lawsuits-against-companies-selling-opioids|title=DOJ to Support Lawsuits Against Companies Selling Opioids|date=2 March 2018|work=Drug Discovery & Development|access-date=2 March 2018|publisher=Advantage Business Media|agency=Associated Press|last2=Mulvihill|first2=Geoff}}

In June 2019, U.S. pharmaceutical company AbbVie announced it had reached an agreement to acquire Allergan for $63 billion, which would return Allergan to the U.S. for tax purposes. On the announcement of the transaction, Abbvie disclosed that its 2019 net effective tax rate was 9%, but that post the acquisition, the Group's effective tax rate would rise to 13%. The merger was expected to close in 2020.

On May 8, 2020, AbbVie completed its acquisition of Allergan.

{{hidden start|toggle=left

|title = Illustration of the company's mergers, acquisitions, spin-offs and historical predecessors

|titlestyle = background:white;

}}

{{clade | style=font-size:90%;line-height:110% |thickness=0

|label1=Allergan, plc
(formerly known as Actavis until June 2015
when it adopted Allergan's name. Acquired by Abbvie June 2019)

|1= {{clade

|label1=

|1= {{clade

|label1=Actavis plc

|1= {{clade

|label1=

|1=Auden Mckenzie Holdings Limited
(Acq 2015)

|3= {{clade

|label1=

|1=Durata Therapeutics
(Acq 2014)

|2=Silom Medical Company
(Acq 2014)

|3= {{clade

|label1=Forest Laboratories
(Acq 2014)

|1= {{clade

|2=Furiex Pharmaceuticals Inc
(Acq 2014)

|1= {{clade

|label1=Aptalis Pharma

|1= {{clade

|1=Axcan Pharma

|2=Eurand Pharmaceuticals

}}}}}}

|4= {{clade

|label1=

|1=Galen
(Acq 2013)

|2=Uteron Pharma, S.A.
(Acq 2013)

|3=Warner Chilcott Plc
(Acq 2000)

|4=Procter & Gamble
(Prescription drug div, Acq 2009)

|5= {{clade

|label1=

|1=Watson Pharmaceuticals

|6= {{clade

|label2=

|1=Andrx Corporation
(Acq 2006)

|label3=

|2=Arrow Group
(Acq 2009)

|label4=

|3=Eden Biodesign

|label5=

|4=Specifar Pharmaceuticals S.A.
(Acq 2011)

|label6=

|5=Ascent Pharmahealth Ltd
(Acq 2012)

|label7=

|6=Actavis Group
(Acq 2012)

}}}}}}}}}}}}

|label2= Allergan, inc

|2= {{clade

|1=Kythera Biopharmaceuticals
(Acq 2015)

|2= {{clade

|1=MAP Pharmaceuticals Inc
(Acq 2013)

|2= {{clade

|1=Inamed Corporation
(Acq 2006)

|2= {{clade

|1=Allergan
(Advanced Medical Optics spun off in 2006)

|2=Janssen-Ortho
Spun off in 2006

|3=Abbott Laboratories
Acq 2007

}}}}}}}}}}

|label3= Allergan, plc

|3= {{clade

|1=Envy Medical, Inc.
(Acq 2019)

|3= {{clade

|1=Repros Therapeutics
(Acq 2017)

|3= {{clade

|1=Keller Medical, Inc
(Acq 2017)

|3= {{clade

|1=Zeltiq Aesthetics Inc.
(Acq 2017)

|3= {{clade

|1=LifeCell
(Acq 2016)

|3= {{clade

|1=Chase Pharmaceuticals
(Acq 2016)

|3= {{clade

|1=Motus Therapeutics
(Acq 2016)

|3= {{clade

|1=Akarna Therapeutics
(Acq 2016)

|3= {{clade

|1=RetroSense Therapeutics
(Acq 2016)

|3= {{clade

|1=ForSight VISION5
(Acq 2016)

|3= {{clade

|1=Tobira Therapeutics
(Acq 2016)

|3= {{clade

|1=Vitae Pharmaceuticals, Inc
(Acq 2016)

|3= {{clade

|1=Topokine Therapeutics
(Acq 2016)

|3= {{clade

|1=Northwood Medical Innovation Ltd
(Acq 2015)

|3= {{clade

|1=AqueSys
(Acq 2015)

|3= {{clade

|1=Naurex Inc
(Acq 2015)

|3= {{clade

|1=Oculeve, Inc
(Acq 2015)

}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}

}}}}

{{hidden end}}

Allergan acquires, develops, manufactures and markets branded products in four therapeutic areas: medical aesthetics, eye care, central nervous system, and gastroenterology. The company manufactures several pharmaceutical products including Botox (botulinum toxin), Juvederm (injectable filler), CoolSculpting (cryolipolysis), Alphagan (brimonidine), Vraylar (cariprazine HCI), Linzess (linaclotide), and Ubrelvy (ubrogepant).{{Cite web|url=https://www.cnbc.com/2019/12/26/migraine-sufferers-have-new-tool-with-approval-of-allergans-ubrelvy.html|title=Migraine sufferers have new oral medication with FDA approval of Allergan's Ubrelvy|last=Bursztynsky|first=Jessica|date=2019-12-26|website=CNBC|language=en|access-date=2020-04-08}}

• Biotech and pharmaceutical companies in the New York metropolitan area
• The St. Regis Mohawk Tribe and Restasis patent
• Corporate tax inversion
• Ireland as a tax haven

{{Reflist|30em}}

• {{official website}}

{{Finance links historical

| name = Allergan plc

| sec_cik = AGN

}}

{{Pharmaceutical companies of the United States}}

{{authority control}}

Category:AbbVie

Category:Companies formerly listed on the New York Stock Exchange

Category:Pharmaceutical companies of Ireland

Category:Manufacturing companies based in Dublin (city)

Category:Pharmaceutical companies established in 2015

Category:Irish companies established in 2015

Category:Tax inversions

Category:2020 mergers and acquisitions

Category:Irish subsidiaries of foreign companies